Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per-Anders Abrahamsson

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Urology|July 4, 2012
The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patientsJan-Erik Damber, Teuvo L J Tammela, Peter Iversen, et al.
Cancer|September 22, 2007
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancerMichael A Carducci, Fred Saad, Per-Anders Abrahamsson, et al.
Urologia Internationalis|July 8, 2010
Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomyNorbert Marschner, Dominik Rüttinger, Gerhard Zugmaier, et al.
International Journal of Experimental Pathology|August 22, 2008
Malignant lesions in the ventral prostate of alloxan-induced diabetic ratsDaniele Lisboa Ribeiro, Silvio Fernando Guideti Marques, Sandra Alberti, et al.
International Journal of Oncology|September 30, 2011
The androgen receptor and stem cell pathways in prostate and bladder cancers (review)Katarzyna Marcinkiewicz, Kymora B Scotland, Stephen A Boorjian, et al.
BJU International|February 20, 2009
Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer StudyFritz H Schröder, Chris H Bangma, Johannes M Wolff, et al.
BJU International|December 2, 2011
Testosterone in prostate cancer: the Bethesda consensusBob Djavan, James Eastham, Leonard Gomella, et al.
European Urology|May 17, 2019
Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019Giorgio Gandaglia, Peter Albers, Per-Anders Abrahamsson, et al.
Oncotarget|September 3, 2016
Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cellsMartuza Sarwar, Julius Semenas, Regina Miftakhova, et al.
Cancer Discovery|May 12, 2012
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigenDavid Ulmert, Michael J Evans, Jason P Holland, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Urology|July 4, 2012
The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patientsJan-Erik Damber, Teuvo L J Tammela, Peter Iversen, et al.
Cancer|September 22, 2007
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancerMichael A Carducci, Fred Saad, Per-Anders Abrahamsson, et al.
Urologia Internationalis|July 8, 2010
Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomyNorbert Marschner, Dominik Rüttinger, Gerhard Zugmaier, et al.
International Journal of Experimental Pathology|August 22, 2008
Malignant lesions in the ventral prostate of alloxan-induced diabetic ratsDaniele Lisboa Ribeiro, Silvio Fernando Guideti Marques, Sandra Alberti, et al.
International Journal of Oncology|September 30, 2011
The androgen receptor and stem cell pathways in prostate and bladder cancers (review)Katarzyna Marcinkiewicz, Kymora B Scotland, Stephen A Boorjian, et al.
BJU International|February 20, 2009
Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer StudyFritz H Schröder, Chris H Bangma, Johannes M Wolff, et al.
BJU International|December 2, 2011
Testosterone in prostate cancer: the Bethesda consensusBob Djavan, James Eastham, Leonard Gomella, et al.
European Urology|May 17, 2019
Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019Giorgio Gandaglia, Peter Albers, Per-Anders Abrahamsson, et al.
Oncotarget|September 3, 2016
Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cellsMartuza Sarwar, Julius Semenas, Regina Miftakhova, et al.
Cancer Discovery|May 12, 2012
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigenDavid Ulmert, Michael J Evans, Jason P Holland, et al.
Pageof 6